YUHAN CORPORATION Logo

YUHAN CORPORATION

A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.

000100 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 동작구 노량진로 74, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuhan Corporation, established in 1926, is a leading South Korean pharmaceutical and chemical company. The firm is primarily engaged in the research, development, manufacturing, and sale of a diverse portfolio of products. Its core business segments include Primary & Specialty care, featuring prescription drugs such as the anticancer treatment Lecraza; dietary supplements; household and animal care products; and the contract manufacturing of active pharmaceutical ingredients (APIs). As a pioneering entity in Korea's pharmaceutical sector, Yuhan Corporation is committed to innovation through its advanced R&D capabilities and manufacturing facilities, while also upholding a strong tradition of social responsibility.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for YUHAN CORPORATION and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-09-02 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 35.6 KB
2025-08-27 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.8 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-18 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 19.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.3 MB

Automate Your Workflow. Get a real-time feed of all YUHAN CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for YUHAN CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea 187420
HLB INC. Logo
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea 028300
HLB Life Science CO.,LTD. Logo
Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.
South Korea 067630
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea 046210
HLB Pep Co., Ltd. Logo
Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.
South Korea 196300
HLB PHARMACEUTICAL CO., LTD. Logo
Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.
South Korea 047920
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea 343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.